Screening for osteoporosis in men receiving androgen deprivation therapy

JAMA

Volumn 307, Issue 3, 2012, Pages 255-256

  Alibhai, Shabbir M H ^a   Yun, Lingsong ^b   Cheung, Angela M ^a   Paszat, Lawrence ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; GONADORELIN AGONIST;

AGED; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; CONTROLLED STUDY; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SCREENING TEST; TREATMENT RESPONSE; ARTICLE; CANADA; CHEMICALLY INDUCED DISORDER; FACTUAL DATABASE; MASS SCREENING; PHOTON ABSORPTIOMETRY; PROSTATE TUMOR; REGISTER; RETROSPECTIVE STUDY; RISK; STATISTICS; UTILIZATION REVIEW;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BONE DENSITY; DATABASES, FACTUAL; HUMANS; MALE; MASS SCREENING; ONTARIO; OSTEOPOROSIS; PROSTATIC NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; RISK;

EID: 84855986641     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.2022     Document Type: Letter

References (6)

1. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615-1624. (Pubitemid 40490022)
2. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27(21): 3452-3458.
3. Duncan GG, Corbett T, Lukka H, Warde P, Pickles T. GU radiation oncologists consensus on bone loss from androgen deprivation. Can J Urol. 2006;13(1): 2962-2966.
4. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-244. (Pubitemid 41043794)
5. Yee EF, White RE, Murata GH, Handanos C, Hoffman RM. Osteoporosis management in prostate cancer patients treated with androgen deprivation therapy. J Gen Intern Med. 2007;22(9):1305-1310. (Pubitemid 47247311)
6. Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med. 2010;152(10):621-629.